Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those that follow publicly traded cannabis companies.
Cannabis Rescheduling Hearing Set to Begin on January 21 for 6 Weeks, As Frustrations Over Process Continue to Build
The Drug Enforcement Administration (DEA) has scheduled an official date for the highly anticipated public hearing on cannabis rescheduling, starting...
